Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Bladder Cancer

Free Subscription Articles published in BJU Int Retrieve available abstracts of 127 articles: HTML format

Single Articles

April 2024
1. LAUKHTINA E, Gontero P, Babjuk M, Moschini M, et al
   Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer.
   BJU Int. 2024 Apr 16. doi: 10.1111/bju.16371.
   PubMed     Abstract available
   
   
   
2. DITONNO F, Veccia A, Montanaro F, Pettenuzzo G, et al
   Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies.
   BJU Int. 2024 Apr 15. doi: 10.1111/bju.16366.
   PubMed     Abstract available
   
   
   
3. LONGONI M, Scilipoti P, Re C, Rosiello G, et al
   Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients.
   BJU Int. 2024 Apr 15. doi: 10.1111/bju.16363.
   PubMed     Abstract available
   
   
   
4. LOBO N, Uthayanan L, Uribe-Lewis S, Issa R, et al
   Gynaecological organ involvement in females undergoing radical cystectomy: a multicentre study.
   BJU Int. 2024;133:474-479.
   PubMed     Abstract available
   
   
   
5. VAN KESSEL CS, Palma CA, Solomon MJ, Leslie S, et al
   Comparison of urological outcomes and quality of life after pelvic exenteration: partial vs radical cystectomy.
   BJU Int. 2024;133 Suppl 4:53-63.
   PubMed     Abstract available
   
   
   
6. BOTROS A, Rival PM, Page F, Davis ID, et al
   Quality of transurethral resection of bladder tumour documentation: implications for non-muscle-invasive bladder cancer risk stratification and management.
   BJU Int. 2024;133 Suppl 4:7-10.
   PubMed    
   
   
   March 2024
7. DE ANGELIS M, Baudo A, Siech C, Jannello LMI, et al
   Trimodal therapy effect on survival in urothelial vs non-urothelial bladder cancer.
   BJU Int. 2024 Mar 18. doi: 10.1111/bju.16333.
   PubMed     Abstract available
   
   
   
8. VON DEIMLING M, Mertens LS, Furrer M, Li R, et al
   The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer.
   BJU Int. 2024 Mar 12. doi: 10.1111/bju.16319.
   PubMed     Abstract available
   
   
   
9. HAYNE D, Ong K, Swarbrick N, McCombie SP, et al
   The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer.
   BJU Int. 2024 Mar 12. doi: 10.1111/bju.16325.
   PubMed     Abstract available
   
   
   February 2024
10. HAAS M, Engelmann SU, Mayr R, Gossler C, et al
    A novel grading approach predicts worse outcomes in stage pT1 non-muscle-invasive bladder cancer.
    BJU Int. 2024 Feb 26. doi: 10.1111/bju.16298.
    PubMed     Abstract available
    
    
    
11. TEMPO JA, Sii S, Ischia J, Bolton DM, et al
    Lessons from a population-based bladder cancer registry: exploring why survival is not improving.
    BJU Int. 2024 Feb 26. doi: 10.1111/bju.16286.
    PubMed     Abstract available
    
    
    
12. CONTIERI R, Tan WS, Grajales V, Hensley PJ, et al
    Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy.
    BJU Int. 2024 Feb 19. doi: 10.1111/bju.16293.
    PubMed     Abstract available
    
    
    
13. 
    Significant advances in chemotherapy for both urothelial and renal cancer.
    BJU Int. 2024;133:122-123.
    PubMed    
    
    
    
14. KLEMM J, Fisch M, Laukhtina E, Dahlem R, et al
    Continent diversion is losing its momentum: a nationwide trend analysis from Germany 2005-2021.
    BJU Int. 2024;133:154-157.
    PubMed    
    
    
    January 2024
15. LU SM, Zhang Y, Dong XT, Wang JL, et al
    Microchip for detection of cell-free DNA in urine to help identify patients with bladder cancer.
    BJU Int. 2024 Jan 30. doi: 10.1111/bju.16271.
    PubMed    
    
    
    
16. YIM A, Alberto M, Sharma V, Green A, et al
    Near-infrared spectroscopy as a novel method of ex vivo bladder cancer tissue characterisation.
    BJU Int. 2024 Jan 18. doi: 10.1111/bju.16226.
    PubMed     Abstract available
    
    
    December 2023
17. VITUG C, Lajkosz K, Chavarriaga J, Llano A, et al
    Long-term outcomes and cost savings of office fulguration of papillary Ta low-grade bladder cancer.
    BJU Int. 2023 Dec 17. doi: 10.1111/bju.16269.
    PubMed     Abstract available
    
    
    
18. HACK J, Douglas J, Makaroff L, Costin M, et al
    Patient Experience of Surveillance Following Radical Treatment for Muscle-Invasive Bladder Cancer.
    BJU Int. 2023 Dec 14. doi: 10.1111/bju.16261.
    PubMed    
    
    
    
19. MASTROIANNI R, Tuderti G, Ferriero M, Anceschi U, et al
    Open versus robot-assisted radical cystectomy: pentafecta and trifecta achievement comparison from a randomised controlled trial.
    BJU Int. 2023;132:671-677.
    PubMed     Abstract available
    
    
    November 2023
20. ROGERS Z, Glaser A, Catto JWF, Bottomley S, et al
    Quality of life after a diagnosis of Bladder Cancer: Longitudinal survey over the first year.
    BJU Int. 2023 Nov 29. doi: 10.1111/bju.16242.
    PubMed     Abstract available
    
    
    October 2023
21. VON DEIMLING M, Furrer M, Mertens LS, Mari A, et al
    Impact of the Extent of Lymph Node Dissection on Survival Outcomes in Clinically Lymph Node-Positive Bladder Cancer.
    BJU Int. 2023 Oct 30. doi: 10.1111/bju.16210.
    PubMed     Abstract available
    
    
    
22. MCELREE IM, Mott SL, O'Donnell MA, Packiam VT, et al
    Alternative instillation techniques of sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer.
    BJU Int. 2023 Oct 19. doi: 10.1111/bju.16208.
    PubMed    
    
    
    
23. NECCHI A, Basile G, Gibb EA, Raggi D, et al
    VI-RADS use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer.
    BJU Int. 2023 Oct 6. doi: 10.1111/bju.16191.
    PubMed     Abstract available
    
    
    
24. VRANG ML, Ostergren PB, Fode MM, Vangedal M, et al
    Robot-assisted radical cystectomy with intracorporeal urinary diversion: a Danish 11-year series.
    BJU Int. 2023;132:428-434.
    PubMed     Abstract available
    
    
    September 2023
25. ZAHRAN MH, Harraz AM, Baset MA, El-Baz R, et al
    Voiding and renal function 10 years after radical cystectomy and orthotopic neobladder in women.
    BJU Int. 2023;132:291-297.
    PubMed     Abstract available
    
    
    August 2023
26. LAUKHTINA E, von Deimling M, Pradere B, Yanagisawa T, et al
    Urinary function in female patients after traditional, organ-and nerve-sparing radical cystectomy for bladder cancer: a systematic review and pooled analyses.
    BJU Int. 2023 Aug 10. doi: 10.1111/bju.16152.
    PubMed     Abstract available
    
    
    July 2023
27. CONTIERI R, Grajales V, Tan WS, Martini A, et al
    Impact of age >70 years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin.
    BJU Int. 2023 Jul 13. doi: 10.1111/bju.16127.
    PubMed     Abstract available
    
    
    
28. JAHNSON S, Jancke G, Olsson H, Aljabery F, et al
    Bladder cancer grading using the four-tier combination of the World Health Organization (WHO) 1973 and WHO 2004 classifications.
    BJU Int. 2023 Jul 6. doi: 10.1111/bju.16100.
    PubMed     Abstract available
    
    
    
29. 
    Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence.
    BJU Int. 2023;132:2-3.
    PubMed    
    
    
    
30. DIAMAND R, D'Hondt F, Mjaess G, Jabbour T, et al
    Teaching robotic cystectomy: prospective pilot clinical validation of the ERUS training curriculum.
    BJU Int. 2023;132:84-91.
    PubMed     Abstract available
    
    
    June 2023
31. BENJAMIN DJ, Lythgoe MP, Rezazadeh A
    Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma.
    BJU Int. 2023;131:691-693.
    PubMed    
    
    
    
32. CATTO JWF, Mandrik O, Quayle LA, Hussain SA, et al
    Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019.
    BJU Int. 2023;131:734-744.
    PubMed     Abstract available
    
    
    
33. TRAIL M, Rahman MSW, Broadhurst WJ, Blackmur JP, et al
    Diagnostic evaluation of upper tract urothelial carcinoma: can we safely omit diagnostic ureteroscopy?
    BJU Int. 2023;131:755-762.
    PubMed     Abstract available
    
    
    
34. DEL GIUDICE F, D'Andrea D, Pradere B, Berndl F, et al
    Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators.
    BJU Int. 2023;131:712-719.
    PubMed     Abstract available
    
    
    May 2023
35. TAN WS, Grajales V, Bree K, Li R, et al
    BCG unresponsive non-muscle invasive bladder cancer: Are the sub-groups equal?
    BJU Int. 2023 May 28. doi: 10.1111/bju.16087.
    PubMed    
    
    
    
36. RICHTERS A, van Ginkel N, Meijer RP, Wondergem M, et al
    Staging FDG-PET/CT for muscle-invasive bladder cancer: A nationwide population-based study.
    BJU Int. 2023 May 28. doi: 10.1111/bju.16091.
    PubMed     Abstract available
    
    
    
37. LAUKHTINA E, Moschini M, Krajewski W, Teoh JY, et al
    Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate.
    BJU Int. 2023;131:571-580.
    PubMed     Abstract available
    
    
    April 2023
38. YANAGISAWA T, Miki J, Sato S, Takahashi H, et al
    Reply to Huseyin Besiroglu's Letter to the editor regarding the article 'Do we need repeat transurethral resection after en-bloc resection for pathological T1 bladder cancer?'.
    BJU Int. 2023 Apr 24. doi: 10.1111/bju.16035.
    PubMed    
    
    
    
39. FREGO N, Contieri R, Diana P, Mancon S, et al
    Inflammatory Markers and Type 2 Diabetes as Prognostic Risk Factors in Low-Risk Bladder Cancer.
    BJU Int. 2023 Apr 5. doi: 10.1111/bju.16026.
    PubMed    
    
    
    
40. ROSE KM, Narang G, Rosen G, Labatte C, et al
    Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study.
    BJU Int. 2023;131:471-476.
    PubMed     Abstract available
    
    
    
41. UCHIMOTO T, Fukushima T, Komura K, Fukuokaya W, et al
    Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
    BJU Int. 2023;131:477-485.
    PubMed     Abstract available
    
    
    March 2023
42. SMELSER WW, Wang J, Ogden KM, Chang SS, et al
    Intravesical Oncolytic Virotherapy and Immunotherapy for Non-Muscle Invasive Bladder Cancer Mouse Model.
    BJU Int. 2023 Mar 24. doi: 10.1111/bju.16012.
    PubMed     Abstract available
    
    
    
43. BESIROGLU H
    Letter to the editor regarding the article 'Do we need repeat transurethral resection after en-bloc resection for pathological T1 bladder cancer?
    BJU Int. 2023 Mar 10. doi: 10.1111/bju.16005.
    PubMed    
    
    
    
44. NURMINEN P, Ettala O, Uusitalo-Seppala R, Hogerman M, et al
    Clinical presentation of bacille Calmette-Guerin (BCG) infections after BCG instillation therapy.
    BJU Int. 2023;131:306-312.
    PubMed     Abstract available
    
    
    February 2023
45. CLAPS F, van de Kamp MW, Mayr R, Bostrom PJ, et al
    Prognostic impact of variant histologies in urothelial bladder cancer treated by radical cystectomy.
    BJU Int. 2023 Feb 6. doi: 10.1111/bju.15984.
    PubMed     Abstract available
    
    
    
46. MIGNOT F, Fabiano E, Xylinas E, Alati A, et al
    Clinical outcomes of adapted hypofractionated radiotherapy for bladder cancer in elderly patients.
    BJU Int. 2023 Feb 6. doi: 10.1111/bju.15983.
    PubMed     Abstract available
    
    
    January 2023
47. VON DEIMLING M, Rink M, Klemm J, Koelker M, et al
    Oncological validation and discriminative ability of pentafecta criteria after open radical cystectomy.
    BJU Int. 2023;131:90-100.
    PubMed     Abstract available
    
    
    December 2022
48. ROBERSON DS, Xia L, Lee DJ, Pierorazio PM, et al
    Comparison of iROC Trial Participants to US Bladder Cancer Patients Undergoing Radical Cystectomy.
    BJU Int. 2022 Dec 22. doi: 10.1111/bju.15954.
    PubMed    
    
    
    
49. YANAGISAWA T, Quhal F, Kawada T, Mostafaei H, et al
    Oncologic Impact of Cystoscopic Findings in Non-Muscle Invasive Bladder Cancer: A Meta-analysis.
    BJU Int. 2022 Dec 7. doi: 10.1111/bju.15944.
    PubMed     Abstract available
    
    
    
50. NEUZILLET Y, Leon P, Seisen T, Allory Y, et al
    A prospective descriptive 1-year study in France of all BCG therapy dispensations for non-muscle-invasive bladder cancer.
    BJU Int. 2022 Dec 3. doi: 10.1111/bju.15941.
    PubMed     Abstract available
    
    
    
51. HUANG C, Assel M, Beech BB, Benfante NE, et al
    Uretero-enteric stricture outcomes: secondary analysis of a randomised controlled trial comparing open versus robot-assisted radical cystectomy.
    BJU Int. 2022;130:809-814.
    PubMed     Abstract available
    
    
    
52. BRAIDE K, Kindblom J, Thellenberg Karlsson C, Stattin P, et al
    Risk of severe late toxicity after radiotherapy following radical prostatectomy - a nationwide study.
    BJU Int. 2022;130:799-808.
    PubMed     Abstract available
    
    
    November 2022
53. GHOREIFI A, Duddalwar V, Djaladat H
    Re: re: risk factors and natural history of parastomal hernia following radical cystectomy and ileal conduit.
    BJU Int. 2022;130:700-701.
    PubMed    
    
    
    
54. HENSLEY PJ, Bree KK, Guo CC, Lobo N, et al
    Clinicopathological analysis and outcomes of inflammatory myofibroblastic tumours of the urinary bladder.
    BJU Int. 2022;130:604-610.
    PubMed     Abstract available
    
    
    
55. MAKRAKIS D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, et al
    Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.
    BJU Int. 2022;130:592-603.
    PubMed     Abstract available
    
    
    September 2022
56. YU EY, Liu YX, Chen YT, Tang QY, et al
    The Effects of Genetic Predisposition Interacted with Lifestyle Factors on Bladder Cancer Risk.
    BJU Int. 2022 Sep 2. doi: 10.1111/bju.15880.
    PubMed     Abstract available
    
    
    
57. 
    Updates on bladder, kidney and prostate cancers.
    BJU Int. 2022;130:275-276.
    PubMed    
    
    
    
58. JOHN JB, Rajaretnam N, McGrath JS, Smart NJ, et al
    Re: risk factors and natural history of parastomal hernia after radical cystectomy and ileal conduit.
    BJU Int. 2022;130:394-395.
    PubMed    
    
    
    
59. VENTIMIGLIA E, Villa L, Salonia A, Traxer O, et al
    Fibre optic ureteroscopes for the management of upper tract urothelial carcinoma? No thanks! Re: Flexible fibre optic vs digital ureteroscopy and enhanced vs unenhanced imaging for diagnosis and treatment of upper tract urothelial carcinoma (UTUC): re
    BJU Int. 2022;130:395-396.
    PubMed    
    
    
    
60. LOBO N, Bree KK, Hensley PJ, Nogueras-Gonzalez GM, et al
    Reduced-dose bacillus Calmette-Guerin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre.
    BJU Int. 2022;130:323-330.
    PubMed     Abstract available
    
    
    
61. GHOREIFI A, Allgood E, Whang G, Douglawi A, et al
    Risk factors and natural history of parastomal hernia after radical cystectomy and ileal conduit.
    BJU Int. 2022;130:381-388.
    PubMed     Abstract available
    
    
    August 2022
62. AHMADI H, Reddy S, Nguyen C, Douglawi A, et al
    Long-term renal function in patients with chronic kidney disease following radical cystectomy and orthotopic neobladder.
    BJU Int. 2022;130:200-207.
    PubMed     Abstract available
    
    
    
63. KOBAYASHI M, Narita S, Matsui Y, Kanda S, et al
    Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.
    BJU Int. 2022;130:226-234.
    PubMed     Abstract available
    
    
    July 2022
64. JAMES ND, Liu W, Pirrie S, Kaur B, et al
    TUXEDO: A phase I/II trial of cetuximab with chemoradiotherapy in muscle-invasive bladder cancer.
    BJU Int. 2022 Jul 31. doi: 10.1111/bju.15864.
    PubMed     Abstract available
    
    
    
65. WALRAVEN JEW, Ripping TM, Oddens JR, van Rhijn BWG, et al
    The influence of multidisciplinary team meetings on treatment decisions in advanced bladder cancer.
    BJU Int. 2022 Jul 21. doi: 10.1111/bju.15856.
    PubMed     Abstract available
    
    
    
66. DADIKHI K, Mueller F, Montani M, Thalmann GN, et al
    Case of the Month from the University Hospital of Bern, Switzerland: Urothelial carcinoma in an orthotopic neobladder: reported cases and pathophysiological hypotheses.
    BJU Int. 2022;130:38-42.
    PubMed    
    
    
    
67. LOIZZO D, Pandolfo SD, Del Giudice F, Cerrato C, et al
    Ureteroscopy and tailored treatment of upper tract urothelial cancer: recent advances and unmet needs.
    BJU Int. 2022;130:35-37.
    PubMed    
    
    
    
68. MAIBOM SL, Roder MA, Aasvang EK, Rohrsted M, et al
    Open vs robot-assisted radical cystectomy (BORARC): a double-blinded, randomised feasibility study.
    BJU Int. 2022;130:102-113.
    PubMed     Abstract available
    
    
    
69. AHMADI H, Ladi-Seyedian SS, Konety B, Pohar K, et al
    Role of blue-light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional registry.
    BJU Int. 2022;130:62-67.
    PubMed     Abstract available
    
    
    
70. GRAHN A, Eisfeldt J, Malm C, Foroughi Asl H, et al
    Genomic profile - a possible diagnostic and prognostic marker in upper tract urothelial carcinoma.
    BJU Int. 2022;130:92-101.
    PubMed     Abstract available
    
    
    June 2022
71. JUBBER I, Mitchell S, Hussain S, Tsoi H, et al
    Social deprivation and bladder cancer: cause or affect for disparities in survival for affected women.
    BJU Int. 2022 Jun 20. doi: 10.1111/bju.15832.
    PubMed    
    
    
    
72. 
    Advances in the management of prostate and bladder cancer and recurrent urinary tract infections.
    BJU Int. 2022;129:659-660.
    PubMed    
    
    
    
73. CONROY S, Hubbard R, Noon AP, Hussain SA, et al
    Case of the month from the University of Sheffield, UK: Expediting definitive treatment in patients with invasive bladder cancer: an MRI-guided pathway.
    BJU Int. 2022;129:691-694.
    PubMed    
    
    
    
74. VEERATTERAPILLAY R, Geraghty R, Pandian R, Roy C, et al
    Ten-year survival outcomes after radical nephroureterectomy with a risk-stratified approach using prior diagnostic ureteroscopy: a single-institution observational retrospective cohort study.
    BJU Int. 2022;129:744-751.
    PubMed     Abstract available
    
    
    
75. NURMINEN P, Ettala O, Uusitalo-Seppala R, Nummi A, et al
    Incidence of and mortality from Bacille Calmette-Guerin (BCG) infections after BCG instillation therapy.
    BJU Int. 2022;129:737-743.
    PubMed     Abstract available
    
    
    April 2022
76. YANAGISAWA T, Sato S, Hayashida Y, Okada Y, et al
    Do we need repeat TUR after en bloc resection for pT1 bladder cancer?
    BJU Int. 2022 Apr 29. doi: 10.1111/bju.15760.
    PubMed     Abstract available
    
    
    
77. HERZBERG H, Lifshitz K, Golan S, Baniel J, et al
    Association between early change in neutrophil-to-lymphocyte ratio after radical cystectomy and treatment outcomes.
    BJU Int. 2022 Apr 27. doi: 10.1111/bju.15757.
    PubMed     Abstract available
    
    
    
78. ALMASSI N, Vertosick EA, Sjoberg DD, Wong NC, et al
    Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy.
    BJU Int. 2022;129:463-469.
    PubMed     Abstract available
    
    
    
79. LEUNBACH TL, Stilling C, Tabor MB, Bjerggaard Jensen J, et al
    Caveats in the diagnosis of suspected non-endemic verrucous carcinoma in the urinary bladder.
    BJU Int. 2022;129:457-459.
    PubMed    
    
    
    
80. SUBIELA JD, Rodriguez Faba O, Aumatell J, Calderon J, et al
    Contemporary outcomes of bladder carcinoma in situ treated with an adequate bacille Calmette-Guerin immunotherapy.
    BJU Int. 2022;129:542-550.
    PubMed     Abstract available
    
    
    March 2022
81. MAISCH P, Koziarz A, Vajgrt J, Narayan V, et al
    Blue versus white light for transurethral resection of non-muscle invasive bladder cancer.
    BJU Int. 2022 Mar 2. doi: 10.1111/bju.15723.
    PubMed     Abstract available
    
    
    
82. HASHEM A, Abdellutif MM, Laymon M, Abdullateef M, et al
    Clinical efficacy of mebeverine for persistent nocturnal enuresis after orthotopic W-neobladder.
    BJU Int. 2022;129:387-393.
    PubMed     Abstract available
    
    
    
83. LEBRET T, Pignot G, Colombel M, Guy L, et al
    Artificial intelligence to improve cytology performances in bladder carcinoma detection: results of the VisioCyt test.
    BJU Int. 2022;129:356-363.
    PubMed     Abstract available
    
    
    February 2022
84. SCHUETTFORT VM, D'Andrea D, Quhal F, Mostafaei H, et al
    A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma.
    BJU Int. 2022;129:182-193.
    PubMed     Abstract available
    
    
    January 2022
85. VAN HOOGSTRATEN LMC, Witjes JA, Meijer RP, Ripping TM, et al
    Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent.
    BJU Int. 2022 Jan 22. doi: 10.1111/bju.15697.
    PubMed     Abstract available
    
    
    
86. ABOZAID M, Tan WS, Khetrapal P, Baker H, et al
    Recovery of health-related quality of life in patients undergoing robot-assisted radical cystectomy with intracorporeal diversion.
    BJU Int. 2022;129:72-79.
    PubMed     Abstract available
    
    
    December 2021
87. MEISL CJ, Karakiewicz PI, Einarsson R, Koch S, et al
    Nomograms including UBC(R) Rapid Test to detect primary bladder cancer based on a multicenter data set.
    BJU Int. 2021 Dec 20. doi: 10.1111/bju.15677.
    PubMed     Abstract available
    
    
    
88. LOBO N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, et al
    Should Patients With Non-Muscle-Invasive Bladder Cancer Discontinue Fibrin Clot Inhibitors During BCG?
    BJU Int. 2021 Dec 1. doi: 10.1111/bju.15665.
    PubMed     Abstract available
    
    
    November 2021
89. LEEMING RC, Karagas MR, Zens MS, Schned AR, et al
    Bladder Cancer Risk Variants and Overall and Disease-Specific Survival in Two Independent Cohorts.
    BJU Int. 2021 Nov 14. doi: 10.1111/bju.15640.
    PubMed     Abstract available
    
    
    
90. HENSLEY PJ, Bree KK, Brooks N, Matulay J, et al
    Time interval from transurethral resection of bladder tumour to bacille Calmette-Guerin induction does not impact therapeutic response.
    BJU Int. 2021;128:634-641.
    PubMed     Abstract available
    
    
    October 2021
91. WETTSTEIN MS, Baxter NN, Sutradhar R, Mamdani M, et al
    Oncological benefit of re-resection for T1 bladder cancer: a comparative effectiveness study.
    BJU Int. 2021 Oct 21. doi: 10.1111/bju.15622.
    PubMed     Abstract available
    
    
    
92. KHADHOURI S, Gallagher KM, MacKenzie KR, Shah TT, et al
    The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study.
    BJU Int. 2021;128:440-450.
    PubMed     Abstract available
    
    
    September 2021
93. GORDON NS, Baxter LA, Goel A, Arnold R, et al
    Urine dna for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: A pilot study.
    BJU Int. 2021 Sep 7. doi: 10.1111/bju.15589.
    PubMed     Abstract available
    
    
    
94. SARI MOTLAGH R, Mori K, Laukhtina E, Aydh A, et al
    Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of non-muscle-invasive bladder cancer: a systematic review and network meta-anal
    BJU Int. 2021;128:280-289.
    PubMed     Abstract available
    
    
    
95. GHODOUSSIPOUR S, Ladi Seyedian SS, Jiang D, Lifton J, et al
    Predictors of need for catheterisation and urinary retention after radical cystectomy and orthotopic neobladder in male patients.
    BJU Int. 2021;128:304-310.
    PubMed     Abstract available
    
    
    August 2021
96. ELSAWY AA, Abol-Enein H, Laymon M, Ahmed AE, et al
    Predictive Value of Immunological Markers after Bacillus Calmette-Guerin Induction in Bladder Cancer.
    BJU Int. 2021 Aug 27. doi: 10.1111/bju.15582.
    PubMed     Abstract available
    
    
    
97. FURRER MA, Papa N, Luetolf S, Roth B, et al
    A longitudinal study evaluating interim assessment of neoadjuvant chemotherapy for bladder cancer.
    BJU Int. 2021 Aug 21. doi: 10.1111/bju.15579.
    PubMed     Abstract available
    
    
    
98. MIYATA Y, Tsurusaki T, Hayashida Y, Imasato Y, et al
    Intravesical MMC and MMC+Ara-C for non-muscle invasive bladder cancer: A randomized clinical trial.
    BJU Int. 2021 Aug 12. doi: 10.1111/bju.15571.
    PubMed     Abstract available
    
    
    
99. ZHOU X, He P, Ji H, Wang C, et al
    Round ligament suspending treatment in orthotopic ileal-neobladder after radical cystectomy in women: a single-centre prospective randomised trial.
    BJU Int. 2021;128:187-195.
    PubMed     Abstract available
    
    
    July 2021
100. LOTAN Y
     Metabolic syndrome and bladder cancer.
     BJU Int. 2021;128:1-2.
     PubMed    
     
     
     June 2021
101. DIRIE J, Mahesan T, Hart E, Janardanan S, et al
     Delivering safe and timely cancer care during COVID-19: lessons and successes from the transition period.
     BJU Int. 2021;127:633-635.
     PubMed    
     
     
     May 2021
102. JAHNSON S, Soderkvist P, Aljabery F, Olsson H, et al
     TERT mutation and the p53 pathway in T1 urinary bladder cancer.
     BJU Int. 2021 May 24. doi: 10.1111/bju.15490.
     PubMed     Abstract available
     
     
     
103. MOE A, Liow E, Redfern A, Swarbrick N, et al
     A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial
     BJU Int. 2021 May 6. doi: 10.1111/bju.15365.
     PubMed     Abstract available
     
     
     
104. MORTEZAVI A, Crippa A, Edeling S, Pokupic S, et al
     Morbidity and mortality after robot-assisted radical cystectomy with intracorporeal urinary diversion in octogenarians: results from the European Association of Urology Robotic Urology Section Scientific Working Group.
     BJU Int. 2021;127:585-595.
     PubMed     Abstract available
     
     
     
105. D'ANDREA D, Matin S, Black PC, Petros FG, et al
     Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
     BJU Int. 2021;127:528-537.
     PubMed     Abstract available
     
     
     April 2021
106. RAVI P, Pond GR, Diamantopoulos LN, Su C, et al
     Optimal Pathologic Response After Neoadjuvant Chemotherapy For Muscle-Invasive Bladder Cancer: Results From A Global, Multi-Center Collaboration.
     BJU Int. 2021 Apr 28. doi: 10.1111/bju.15434.
     PubMed     Abstract available
     
     
     
107. COWAN B, Klein E, Jansz K, Westenfelder K, et al
     Longitudinal Follow-up and Performance Validation of a mRNA-based Urine Test (Xpert(R) Bladder Cancer Monitor) for surveillance in Non-Muscle Invasive Bladder Cancer Patients.
     BJU Int. 2021 Apr 1. doi: 10.1111/bju.15418.
     PubMed     Abstract available
     
     
     March 2021
108. STROTHER MC, Kutikov A, Epstein M, Bochner E, et al
     Safety of Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer and Malignant Ureteral Obstruction.
     BJU Int. 2021 Mar 29. doi: 10.1111/bju.15410.
     PubMed     Abstract available
     
     
     
109. FICARRA V, Crestani A, Rossanese M, Alario G, et al
     Retrosigmoid ileal conduit without transposition of the left ureter after open radical cystectomy for bladder cancer.
     BJU Int. 2021 Mar 10. doi: 10.1111/bju.15375.
     PubMed     Abstract available
     
     
     February 2021
110. ABRAHAMSSON J, Kollberg P, Almquist H, Blackberg M, et al
     Complete Metabolic Response with FDG-PET-CT Predicts Survival after Induction Chemotherapy in patients with Clinically Node-positive Bladder Cancer.
     BJU Int. 2021 Feb 24. doi: 10.1111/bju.15374.
     PubMed     Abstract available
     
     
     
111. MIYAKE M, Nakai Y, Nishimura N, Ohnishi S, et al
     Hexylaminolevulinate-mediated fluorescent urine cytology with a novel automated detection technology for screening and surveillance of bladder cancer.
     BJU Int. 2021 Feb 12. doi: 10.1111/bju.15368.
     PubMed     Abstract available
     
     
     January 2021
112. BREE KK, Hensley PJ, Brooks NA, Matulay J, et al
     Impact of upper tract urothelial carcinoma on response to bcg in patients with non-muscle invasive bladder cancer.
     BJU Int. 2021 Jan 22. doi: 10.1111/bju.15344.
     PubMed     Abstract available
     
     
     
113. DUNSMORE J, Duncan E, Mariappan P, de Bruin M, et al
     What influences adherence to guidance for post-operative instillation of intravesical chemotherapy to bladder cancer patients?
     BJU Int. 2021 Jan 15. doi: 10.1111/bju.15336.
     PubMed     Abstract available
     
     
     
114. RICHTERS A, Ripping TM, Kiemeney LA, Leliveld AM, et al
     Hospital volume is associated with postoperative mortality following radical cystectomy for treatment of bladder cancer.
     BJU Int. 2021 Jan 6. doi: 10.1111/bju.15334.
     PubMed     Abstract available
     
     
     
115. FUKUOKAYA W, Kimura T, Yanagisawa T, Kimura S, et al
     Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab.
     BJU Int. 2021;127:90-95.
     PubMed     Abstract available
     
     
     December 2020
116. STANGL FP, Thalmann GN
     Continent diversion: five decades of developments and evolution.
     BJU Int. 2020;126:653-660.
     PubMed     Abstract available
     
     
     
117. MUILWIJK T, Akand M, Soria F, Giordano A, et al
     The Cancer of the Bladder Risk Assessment (COBRA) score for estimating cancer-specific survival after radical cystectomy: external validation in a large bi-institutional cohort.
     BJU Int. 2020;126:704-714.
     PubMed     Abstract available
     
     
     November 2020
118. BROOKS NA, Kokorovic A, Xiao L, Matulay JT, et al
     The Obesity Paradox: Defining the impact of Body Mass Index and Diabetes Mellitus for patients with Non-Muscle Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin.
     BJU Int. 2020 Nov 14. doi: 10.1111/bju.15296.
     PubMed     Abstract available
     
     
     
119. SORIA F, Black PC, Fairey AS, Cookson MS, et al
     Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis.
     BJU Int. 2020 Nov 5. doi: 10.1111/bju.15289.
     PubMed     Abstract available
     
     
     
120. DEL GIUDICE F, Leonardo C, Simone G, Pecoraro M, et al
     Preoperative detection of Vesical Imaging-Reporting and Data System (VI-RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the
     BJU Int. 2020;126:610-619.
     PubMed     Abstract available
     
     
     October 2020
121. SPENCER-BOWDAGE S, Russell B, Rigby J, O'Kelly J, et al
     The experience of UK bladder cancer patients during the COVID-19 pandemic: A survey-based snapshot.
     BJU Int. 2020 Oct 30. doi: 10.1111/bju.15287.
     PubMed     Abstract available
     
     
     
122. KARDOUST PARIZI M, Shariat SF, Margulis V, Mori K, et al
     Tumor infiltrating immune cells to predict response to intravesical BCG in Patients with Non-muscle invasive Bladder Cancer: A Systematic Review and meta-analysis.
     BJU Int. 2020 Oct 18. doi: 10.1111/bju.15276.
     PubMed     Abstract available
     
     
     
123. HOSSEINI A, Mortezavi A, Sjoberg S, Laurin O, et al
     Robot-assisted intracorporeal orthotopic bladder substitution after radical cystectomy: perioperative morbidity and oncological outcomes - a single-institution experience.
     BJU Int. 2020;126:464-471.
     PubMed     Abstract available
     
     
     September 2020
124. LENFANT L, Cancel-Tassin G, Gazut S, Comperat E, et al
     Genetic variability in 13q33 and 9q34 is linked to Aggressiveness Patterns and a Higher risk of progression of Non-Muscle-Invasive Bladder Cancer at the time of Diagnosis.
     BJU Int. 2020 Sep 25. doi: 10.1111/bju.15254.
     PubMed     Abstract available
     
     
     
125. VAN DER VLIES E, Los M, Stijns PEF, van Hengel M, et al
     Preoperative frailty and outcome in patients undergoing radical cystectomy.
     BJU Int. 2020;126:388-395.
     PubMed     Abstract available
     
     
     August 2020
126. HUSSEIN AA, Elsayed AS, Aldhaam NA, Jing Z, et al
     A comparative propensity score-matched analysis of perioperative outcomes of intracorporeal vs extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.
     BJU Int. 2020;126:265-272.
     PubMed     Abstract available
     
     
     June 2020
127. SARI MOTLAGH R, Mori K, Miura N, Quhal F, et al
     The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumor and benign prostatic hyperplasia; a systematic review and meta-analysis.
     BJU Int. 2020 Jun 21. doi: 10.1111/bju.15146.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.